AstraZeneca raises profit outlook on strong medicines demand
Expects 2024 sales and profit to grow by a mid teens percentage
Q2 sales of $12.94 billion beat forecast, core EPS $1.98 in line
Shares fell as much as 4%
Updates shares in paragraph 4
By Pushkala Aripaka and Maggie Fick
July 25 (Reuters) -Anglo-Swedish drugmaker AstraZeneca AZN.L raised its full year sales and profit forecast on Thursday after beating analyst expectations for second-quarter revenue on strong demand for its cancer, rare disease and heart disease medicines.
Sales in AstraZeneca's top business, oncology, grew 19% at constant currency rates to $5.33 billion and accounted for 41% of the total, while its rare disease and heart and kidney disease divisions also each raked in double-digit growth.
Second-quarter profit though was dented by a rise in expenses and sales of cancer drugs Enhertu and Imfinzi were slightly softer than expected, analysts said.
The shares slipped by as much as 4%. They were down 2.4% at 1000GMT after gains of about 14% so far this year. But on Thursday they wereone of the worst performers in the European pharma sector, which was down 0.14% .SXDP.
British rival GSK's GSK.L shares are up 4.1% this year and Swiss drugmaker Roche ROG.S is up 11% this year, compared with the STOXX 600 Index gains of 7%.
AstraZeneca expects both 2024 revenue and core earnings per share to increase by a mid-teens percentage at constant currency rates, it said. It had previously expected revenue and profit to increase by a low double-digit to low-teens percentage.
The UK's most valuable company in terms of its market capitalisation of 189.4 billion pounds ($243.89 billion) has evolved significantly since CEO Pascal Soriot took over 12 years ago. New technologies such as antibody-drug conjugates are making up a rising proportion of its future cancer therapies.
The sales outlook reflects how the company has moved beyond the COVID vaccine, its best-selling product at the height of the pandemic in 2021, thanks to its roster of cancer therapies and a strong pipeline, including new treatments in other disease areas by the end of the decade.
"In the year to date we have continued to make encouraging progress with several disruptive technologies ... all of which have the potential to drive our growth beyond 2030," CEO Soriot said in a statement.
At its investor day in May, the company announced it aimed to grow revenue by about 75% to $80 billion by 2030, citing the expected launch of 20 new medicines and growth in its cancer, biopharmaceuticals and rare disease portfolio.
The company has been investing in building its pipeline and marketing new launches. In May, AstraZeneca said that a plant in Qingdao, China, will help it build a distinct local supply chain to serve the Chinese market, its second largest globally.
Operating expenses in the quarter were 14% higher at $6.74 billion.
Total revenue rose 17% on a constant-currency basis to $12.94 billion for the three months ended June, while core earnings came in at $1.98 per share, compared with analysts' average expectation of $12.6 billion and $1.98 per share, respectively, according to a company-compiled consensus.
AstraZeneca increased its interim dividend by 7 cents to $1.
($1 = 0.7766 pounds)
Reporting by Pushkala Aripaka in Bengaluru and Maggie Fick in London; Editing by Sonia Cheema and Elaine Hardcastle
Ativos relacionados
Últimas notícias
Isenção de Responsabilidade: As entidades do XM Group proporcionam serviço de apenas-execução e acesso à nossa plataforma online de negociação, permitindo a visualização e/ou uso do conteúdo disponível no website ou através deste, o que não se destina a alterar ou a expandir o supracitado. Tal acesso e uso estão sempre sujeitos a: (i) Termos e Condições; (ii) Avisos de Risco; e (iii) Termos de Responsabilidade. Este, é desta forma, fornecido como informação generalizada. Particularmente, por favor esteja ciente que os conteúdos da nossa plataforma online de negociação não constituem solicitação ou oferta para iniciar qualquer transação nos mercados financeiros. Negociar em qualquer mercado financeiro envolve um nível de risco significativo de perda do capital.
Todo o material publicado na nossa plataforma de negociação online tem apenas objetivos educacionais/informativos e não contém — e não deve ser considerado conter — conselhos e recomendações financeiras, de negociação ou fiscalidade de investimentos, registo de preços de negociação, oferta e solicitação de transação em qualquer instrumento financeiro ou promoção financeira não solicitada direcionadas a si.
Qual conteúdo obtido por uma terceira parte, assim como o conteúdo preparado pela XM, tais como, opiniões, pesquisa, análises, preços, outra informação ou links para websites de terceiras partes contidos neste website são prestados "no estado em que se encontram", como um comentário de mercado generalizado e não constitui conselho de investimento. Na medida em que qualquer conteúdo é construído como pesquisa de investimento, deve considerar e aceitar que este não tem como objetivo e nem foi preparado de acordo com os requisitos legais concebidos para promover a independência da pesquisa de investimento, desta forma, deve ser considerado material de marketing sob as leis e regulações relevantes. Por favor, certifique-se que leu e compreendeu a nossa Notificação sobre Pesquisa de Investimento não-independente e o Aviso de Risco, relativos à informação supracitada, os quais podem ser acedidos aqui.
